Spasmocalm (Drotaverine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Spasmocalm (Drotaverine)

Advertisements
Advertisements

Overview of Spasmocalm (Drotaverine)

What Type of Medicine is Spasmocalm (Drotaverine)?

Drotaverine is an active pharmaceutical ingredient classified as a spasmolytic agent (Antispasmodic drug) designed for the relief of involuntary muscular contractions. Chemically, it is a synthetic pharmaceutical and a benzylisoquinoline derivative. The substance is widely classified under the ATC system with the code A03AD02. This designation reflects its specific properties as a smooth muscle relaxant.

Composition and Forms of Drotaverine

Drotaverine is manufactured as a single-ingredient product, containing the active compound Drotaverine Hydrochloride. The drug is available in two primary dosage forms: oral tablets and a solution for injection intended for intramuscular or intravenous administration. The tablets are formulated with pharmaceutical excipients, while the injectable form utilizes an aqueous solution. These different formats allow for application ranging from standard oral intake to rapid clinical use.

What is the General Purpose of This Spasmolytic Agent?

The primary purpose of Drotaverine is to facilitate smooth muscle relaxation, which helps reduce the discomfort associated with involuntary muscular contractions, often described as spasms or cramps. It exerts a myotropic action, directly affecting the smooth muscle cells of the internal organs. The pharmacological process involves acting as a selective phosphodiesterase-4 (PDE4) inhibitor, which helps resolve the underlying muscular tension that leads to cramp-like sensations.

Advertisements

What side effects are possible with Spasmocalm (Drotaverine)?

The documented safety profile of Drotaverine Hydrochloride is defined by official clinical and post-marketing data, with adverse reactions organized according to the physiological system affected. Frequency classifications are consistent with regulatory terminology, where most documented undesirable effects are typically categorized as rare.

Official Adverse Reactions and System Groupings

Adverse effects listed in official documents include reactions across several System-Organ Classes. Effects affecting the Nervous System may include headache, dizziness, and insomnia. Reactions involving the Gastrointestinal System include nausea and constipation. The Cardiovascular System may be affected, with documented effects such as palpitations, tachycardia, arrhythmia, and hypotension (low blood pressure).

Manifestations within the Immune System have been noted, primarily signs of hypersensitivity, which can include local skin reactions such as rash, pruritus (itchy skin), and angioedema (swelling). Serious adverse reactions, documented as extremely rare, include anaphylactic reactions and bronchospasm.

Safety Restrictions and Population Considerations

The medicine is subject to defined safety restrictions (contraindications) specified in regulatory labeling. Drotaverine is contraindicated in individuals with known hypersensitivity to the active ingredient, as well as those with established severe hepatic, severe renal, or low output cardiac insufficiency. Further absolute restrictions include pre-existing cardiac conditions such as second- or third-degree atrioventricular (AV) block, cardiogenic shock, and severe arterial hypotension.

Official labeling also defines specific constraints for certain populations: the use of Drotaverine is contraindicated in children below the age of six years due to insufficient safety data. Use during pregnancy and breastfeeding is generally not recommended, and use requires a careful risk assessment as defined by regulatory authorities.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Drotaverine based on documented clinical manifestations and severe potential outcomes. Overdose may present with systemic signs including weakness, malaise, dizziness, headache, and vomiting. Further documented clinical findings include hypotension (a significant drop in blood pressure) and various heart rhythm and conduction disorders.

In severe cases, regulators have noted the risk of life-threatening events. These outcomes may include a Potentially fatal complete bundle block, cardiac arrest, and paralysis of the respiratory center.

Due to the risk of severe complications, the regulatory framework mandates that users contact a doctor or emergency services immediately if an accidental or intentional overdose is suspected. Hospital monitoring, often requiring medical observation for at least 48 hours, may be necessary for comprehensive management.

Official management procedures focus on supportive care, as no specific antidote is detailed in the regulatory labeling. Treatment typically involves providing symptomatic and supportive treatment to address clinical signs. Measures to reduce drug absorption, such as gastric lavage or the administration of activated charcoal, are procedures that may be initiated by medical personnel.

Advertisements

Therapeutic Uses of Spasmocalm (Drotaverine)

What Spasmocalm (Drotaverine) Treats: Main Uses and Benefits

Drotaverine (Spasmocalm) is used in areas where short-term symptom management is appropriate, particularly in contexts marked by increased discomfort or tension.

In therapeutic settings, Drotaverine is commonly used to help with symptoms related to systemic imbalance, including those associated with gastrointestinal, biliary tract, and urinary tract disorders, as well as symptoms related to menstrual discomfort. This medication contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.


Relief for Disruptive Symptom Manifestations

This domain covers symptoms that interfere with daily functioning and create noticeable physiological strain, which can appear in conditions involving episodic or fluctuating manifestations. It is commonly used when short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden. This supportive relief helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relevant for managing symptoms that interfere with daily comfort


Addressing Episodic and Fluctuating Symptom Patterns

This category addresses symptom clusters that may become intense or disruptive, which can be relevant in conditions characterized by periods of heightened symptoms. Applied in scenarios where additional management of discomfort is required, the medication supports patients during difficult episodes and may help them cope more steadily with symptom fluctuations.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Spasmocalm (Drotaverine)?

Official regulatory documents define strict population-based eligibility for Drotaverine use, focusing on absolute contraindications and conditional restrictions.

Contraindicated Populations

Use of Drotaverine is contraindicated (must not be used) in individuals with specific severe health conditions, as stated in the regulatory label:

  • Severe Organ Dysfunction: Patients with severe hepatic insufficiency or severe renal insufficiency.
  • Severe Cardiac Conditions: Individuals with severe heart failure, particularly low output syndrome, or certain severe cardiac conduction disorders such as AV blockade II and III grades.
  • Hypersensitivity: Those with a known allergy to drotaverine hydrochloride or any of the product’s ingredients.

Age-Related Eligibility and Restrictions

Population Group Eligibility Status (Regulatory Basis)
Children Under 6 Years Contraindicated or Not Recommended; no sufficient data are available.
Children 6 Years and Older Eligible for use, with maximum daily dosages formally specified for the 6-12 age group and the above 12 age group.
Adults Eligible for use under standard labeled conditions.
Elderly Use requires formal caution in the elderly population.

Conditional Use and Physiological Status

Use requires formal caution in patients with less severe impaired hepatic or renal function and individuals with hypotension (low blood pressure). The regulatory status during pregnancy is either caution should be taken or should not be used, depending on the authority. Use is not recommended for women who are lactating (breastfeeding).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Drotaverine establishes several documented interaction patterns, primarily categorized as pharmacodynamic or exposure-modifying effects.


Contraindicated Combination

Interacting Product Official Restriction
Levodopa (Anti-Parkinsonian Agent) Co-administration is formally contraindicated (prohibited). Drotaverine is documented to reduce the anti-Parkinsonian efficacy of Levodopa, which may lead to increased muscle rigidity and tremor.

Other Documented Interactions

Drotaverine’s interaction profile is largely defined by pharmacodynamic synergy, resulting in additive effects on certain physiological processes.

Interacting Class/Product Official Interaction Statement
Other Spasmolytics Risk of an additive spasmolytic effect (enhanced muscle relaxation).
Tricyclic Antidepressants, Procainamide May result in enhanced hypotensive effects (blood pressure lowering).
Opioid Analgesics (e.g., Morphine) Documented to reduce the spasmogenic activity of the opioid analgesic.
Magnesium Hydroxide May increase the absorption of Drotaverine, which is an exposure-modifying effect.
Alcohol Regulatory advice suggests avoidance as it may increase the incidence of dizziness.

No formal pharmacokinetic interactions (e.g., specific CYP enzyme inhibition) are explicitly detailed in the official prescribing information as defined interaction mechanisms requiring dose adjustment. There are also no mandatory timing-separation rules documented.

Advertisements

Mechanism of Action

How Drotaverine Modulates Smooth Muscle Activity

Drotaverine acts as an agent whose primary mechanism is a direct action on smooth muscle cells, modulating the contractile process independent of the nervous system. The compound exerts its physiological influence through two core mechanistic domains that alter the muscle cell's ability to contract.

Selective Inhibition of the PDE4 Enzyme System

The central action involves the selective inhibition of the intracellular enzyme Phosphodiesterase-4 ( PDE4). PDE4 mediates the hydrolysis of the critical cellular messenger cyclic AMP ( cAMP). By inhibiting PDE4, Drotaverine causes cAMP concentration to rise significantly. This rise triggers a downstream cascade that ultimately inactivates Myosin Light Chain Kinase ( MLCK), an enzyme involved in regulating contraction.

Modulation of Intracellular Calcium Dynamics

This effect is augmented by a secondary action on calcium ( Ca^2+) ion homeostasis. Drotaverine acts as a minor blocker of Voltage-Dependent L-type Calcium Channels ( L-VDCC). This reduces Ca^2+ influx, which further limits the ion's availability for triggering the contractile cycle. The combined molecular effect leads to a substantial deactivation of the contractile apparatus and subsequent smooth muscle fiber lengthening (relaxation) in the visceral systems.

Advertisements

Dosage and Administration Information

How to Use Spasmocalm (Drotaverine): Official Administration Guidelines

Drotaverine is administered via two primary methods: oral tablets and a solution for injection suitable for both intramuscular (IM) and intravenous (IV) routes. The specific method of use and dosing depend on the clinical context.


Standard Dosage and Frequency

Official prescribing information defines strict dose ranges and frequency patterns to ensure proper use:

Population Dosage Form Recommended Daily Dose Range Frequency
Adults Oral Tablets 120 mg to 240 mg In 2 to 3 divided doses
Adults Injection (IM/IV) 40 mg to 240 mg 1 to 3 times per day
Children (6–12 years) Oral Tablets Max. 80 mg In 2 divided doses
Children (>12 years) Oral Tablets Max. 160 mg In 2 to 4 divided doses

Administration Requirements

Certain procedural conditions must be observed for proper administration, and the maximum recommended daily dose must not be exceeded in any population.

  • Oral Intake: Tablets should be swallowed with a full glass of water.
  • Intravenous Use: When the solution is administered intravenously, especially for acute symptoms, it must be injected slowly (e.g., over approximately 30 seconds) in a supervised setting.
  • Missed Dose: If a dose is missed, it should be taken when realized. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent doubling the dosage.

These official instructions define the standardized, label-based approach for the safe and appropriate use of Drotaverine across its approved administration routes and forms.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Spasmocalm (Drotaverine)


Evidence for Studies on Gastrointestinal Spasmodic Pain

Research exploring the use of Drotaverine has primarily utilized short-term Randomized Controlled Trials (RCTs) and comparative studies to examine the compound’s impact on painful gastrointestinal symptoms. These studies were conducted during periods of increased symptom activity and focused on adults who experienced conditions characterized by fluctuating or episodic manifestations. Researchers typically measured patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort and systemic functional imbalance. Studies monitored patterns and reported findings related to changes in abdominal pain scores and the frequency of painful episodes when compared to control groups over defined, short time intervals.

Evidence for Acute Colic and Biliary Tract Spasms

Studies focusing on acute spasmodic pain—like that from renal or biliary colic—were typically conducted as acute-phase RCTs in emergency or hospital settings. The research examined outcomes describing episodic or acute changes in adults in the context of acute or disruptive episodes. Researchers monitored outcomes related to physical discomfort by measuring the intensity of pain at short intervals and observed the need for rescue pain medication. Research monitored and reported patterns related to measured changes in pain severity in the observed populations during the acute episode. The evidence base is generally labeled as Moderate in consistency for these specific, short-term, acute research scenarios.

Evidence for Menstrual Discomfort (Dysmenorrhea)

Research into Drotaverine for menstrual discomfort (dysmenorrhea) has been conducted primarily using RCTs and comparative trials involving young to middle-aged adult women. These studies were used in research exploring how symptoms change over time in conditions involving periods of heightened symptoms. Outcomes related to physical discomfort were a key focus, and studies monitored the change in self-reported pain intensity over defined short intervals and the patient's overall perceived discomfort. Studies contribute to understanding symptom patterns in the observed populations, with some research highlighting measured changes during the study period compared to placebo.

Research Gaps and Areas of Uncertainty

The overall evidence landscape highlights what is known—and what is still uncertain. Key limitations apply across the research, including reliance on modest sample sizes and limited follow-up durations (e.g., a few weeks). There is limited information for long-term outcomes, the consequences of prolonged use, or for specific populations such as pediatric patients or older adults with multiple health conditions.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Spasmocalm (Drotaverine) (FAQ)


Q: Is Spasmocalm a narcotic or addictive medicine?

Drotaverine, the active ingredient in Spasmocalm, is classified as a spasmolytic agent, meaning its function is to relax smooth muscle cells. Official descriptions indicate that it acts directly on the muscle and practically does not influence the central nervous system. This action is consistent with a drug that is not primarily directed at the central nervous system.


Q: What should I do if a side effect of Spasmocalm feels severe?

Regulatory documents define certain severe adverse reactions, such as signs of a severe allergic reaction like anaphylactic reactions or bronchospasm. Such specific symptoms are considered serious reactions, and official guidance on serious events generally advises seeking immediate medical attention.


Q: Is there a difference in how Spasmocalm works compared to Buscopan (Hyoscine Butylbromide)?

Yes, their pharmacological mechanisms are different. Drotaverine is officially described as a selective phosphodiesterase-4 (PDE4) inhibitor that acts directly on the muscle cells themselves to promote relaxation. This mechanism of action is distinct from other antispasmodic agents that work by affecting the nervous system.


Q: Does Spasmocalm affect blood pressure?

Official documents list hypotension (low blood pressure) as a documented cardiovascular adverse reaction to Drotaverine. Furthermore, regulatory information notes that taking Drotaverine with certain other medications may result in enhanced hypotensive effects. The potential for low blood pressure effects defines the need for caution in certain populations.


Q: Does taking Spasmocalm with food change how it works?

Official regulatory information specifies that oral tablets should be swallowed with a full glass of water. Specific formal requirements regarding the concurrent intake of food are not detailed in some official documents.


Q: What is the legal classification of Spasmocalm (prescription vs. non-prescription)?

The legal classification of Drotaverine can vary by country. For example, regulatory bodies in some areas classify the oral tablets as Over-The-Counter (OTC), while the solution for injection is classified as prescription-only (Rx-only).


Q: What is the difference between an antispasmodic and a regular pain reliever?

Drotaverine is classified as a spasmolytic agent (antispasmodic). Its documented purpose is to relieve pain by reducing the tension and involuntary contractions of smooth muscle cells. This targeted action is distinct from a general analgesic, which is primarily intended for broad pain relief.


Q: Does Spasmocalm treat pain that isn't related to spasms?

The documented purpose of Drotaverine is to reduce pain and discomfort that is specifically caused by involuntary muscular contraction, or spasm. This definition suggests its action is targeted at spasm-related pain.


Q: How quickly can I expect Spasmocalm to start working?

Studies on Drotaverine's pharmacokinetics report that the time to reach peak concentration in the blood is around 45 to 60 minutes after taking an oral dose. Reports indicate that relief is typically observed within the first hour of administration.


Q: How long does the effect of Spasmocalm usually last?

The effect of Drotaverine is generally reported in studies to last for approximately 4 to 6 hours. This duration is consistent with the need for multi-dose schedules, as outlined in official prescribing information.


Q: Are there any common side effects people report when taking Spasmocalm?

Official regulatory information provides frequency classifications for adverse effects. The majority of documented undesirable effects, including nervous system and cardiovascular reactions, are classified using low-frequency terms such as rare.


Q: Is it normal to feel dizzy after taking Spasmocalm?

Dizziness is a possible reaction listed in official documents as affecting the Nervous System. It is a documented effect that has been reported during use.


Q: Can Spasmocalm cause problems with my stomach or digestion?

Yes, documented adverse reactions involving the Gastrointestinal System are listed in the official safety profile. These include reports of nausea and constipation.


Q: Are there any specific food or drinks to avoid while taking Spasmocalm?

Regulatory advice suggests avoiding alcohol while using Drotaverine. This is due to the potential for the combination to increase the reported incidence of dizziness.


Q: Is Drotaverine used for spasms related to Irritable Bowel Syndrome (IBS)?

Regulatory literature and research indicate that Drotaverine is used to support the treatment of gastrointestinal smooth muscle spasms. This includes spasms associated with conditions such as Irritable Bowel Syndrome (IBS).


Q: Is it true that Drotaverine is not approved by the FDA?

Official regulatory literature indicates that Drotaverine is not approved by certain regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada.

Advertisements

How should Spasmocalm (Drotaverine) be stored and disposed of?

Drotaverine tablets must be stored according to official regulatory requirements to maintain product stability and quality.

Storage Requirements

The product should be stored at a temperature below 25 C or not exceeding 30 C, depending on the specific label, and must be kept in a cool, dry, and dark place. Protection from light and moisture is required. The medicine must remain in the original packaging with the container tightly closed and stored out of the sight and reach of children.

Disposal Instructions

Unused or expired drotaverine product should be disposed of in accordance with local requirements; it must not be disposed of via wastewater or household waste. The recommended method is returning the medicine through a drug take-back program. If this is not available, the product should be mixed with an undesirable substance, sealed, and discarded in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spasmocalm (Drotaverine) found in:

A-Z Index: